Mutz Mitchell 4
4 · Pandion Therapeutics, Inc. · Filed Jul 23, 2020
Insider Transaction Report
Form 4
Mutz Mitchell
Director10% Owner
Transactions
- Purchase
Common Stock
2020-07-21$18.00/sh+10,000$180,000→ 10,000 total(indirect: By Spouse) - Conversion
Common Stock
2020-07-21+3,049,973→ 3,049,973 total(indirect: See footnote) - Conversion
Series B Preferred Stock
2020-07-21−2,414,098→ 0 total(indirect: See footnote)→ Common Stock (473,409 underlying) - Conversion
Series A Preferred Stock
2020-07-21−13,138,905→ 0 total(indirect: See footnote)→ Common Stock (2,576,564 underlying) - Purchase
Common Stock
2020-07-21$18.00/sh+36,111$649,998→ 3,086,084 total(indirect: See footnote)
Footnotes (3)
- [F1]The Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- [F2]Roche Finance Ltd ("Roche Finance") is the direct beneficial owner of these securities of the Issuer. Roche Finance is a wholly owned subsidiary of Roche Holding Ltd. Roche Holding Ltd is the indirect beneficial owner of these securities of the Issuer.
- [F3]Represents shares purchased by Mr. Mutz's wife through a directed share program in connection with the initial public offering of Pandion Therapeutics, Inc.'s common stock, which closed on July 21, 2020. These shares of common stock were purchased at the public offering price of $18.00 per share.